ConductScience.org, home

Paper2402017

Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity.

Kelner MJ and 2 others. J Natl Cancer Inst, 1990. Cited by 74 papers, by iCite.

Cite this record

ConductScience Library. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. Papers, record 2402017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2402017

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1990
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
74
iCite
Relative citation ratio, by iCite
2.05
iCite
Revised in PubMed
2019-12-10
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kelner MJM J
2McMorris TCT C
3Taetle RR

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibiotics, AntineoplasticMajor topic
Drug Screening Assays, AntitumorMajor topic
Animals
Biological Transport
Cell Line
Cell Survival
Humans
Kinetics
Polycyclic Sesquiterpenes
Sesquiterpenes

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA-23100NCI NIH HHSUnited StatesP30CA023100PubMed and NIHNIH RePORTER
CA-45568NCI NIH HHSUnited StatesR01CA045568PubMed and NIHNIH RePORTER
RR-08135NCRR NIH HHSUnited StatesS06RR008135PubMed and NIHNIH RePORTER

Download CSV of grants

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 74 citations.

PMIDTitleJournalYearIn PapersSource
42634105Mycotoxins in Basidiomycete Mycelium and Fruiting Bodies: Implications for Eu Novel Food Assessment and Selected International Regulatory Frameworks.Compr Rev Food Sci Food Saf2026https://conductscience.org/library/papers/42634105PubMed
39858827Spore-Derived Isolates from a Single Basidiocarp of Bioluminescent Omphalotus olivascens Reveal Multifaceted Phenotypic and Physiological Variations.Microorganisms2025https://conductscience.org/library/papers/39858827PubMed
36012321Antitumor Effects of a New Retinoate of the Fungal Cytotoxin Illudin M in Brain Tumor Models.Int J Mol Sci2022https://conductscience.org/library/papers/36012321PubMed
35843931Optimization of the production process for the anticancer lead compound illudin M: process development in stirred tank bioreactors.Microb Cell Fact2022https://conductscience.org/library/papers/35843931PubMed
35643529Optimization of the production process for the anticancer lead compound illudin M: improving titers in shake-flasks.Microb Cell Fact2022https://conductscience.org/library/papers/35643529PubMed
22895897Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent.J Pharmacol Exp Ther2012https://conductscience.org/library/papers/22895897PubMed
21939268Chemical and enzymatic reductive activation of acylfulvene to isomeric cytotoxic reactive intermediates.Chem Res Toxicol2011https://conductscience.org/library/papers/21939268PubMed
21443269Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.Chem Res Toxicol2011https://conductscience.org/library/papers/21443269PubMed
20160945Observations in the Synthesis of the Core of the Antitumor Illudins via an Enyne Ring Closing Metathesis Cascade.Tetrahedron Lett2009https://conductscience.org/library/papers/20160945PubMed
19938810Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.J Org Chem2009https://conductscience.org/library/papers/19938810PubMed
19668867Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues.Mol Biosyst2009https://conductscience.org/library/papers/19668867PubMed
17628744A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.Invest New Drugs2007https://conductscience.org/library/papers/17628744PubMed
16683074A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.Invest New Drugs2006https://conductscience.org/library/papers/16683074PubMed
12201500A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.Invest New Drugs2002https://conductscience.org/library/papers/12201500PubMed
11561687Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.Invest New Drugs2001https://conductscience.org/library/papers/11561687PubMed
11291837A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.Invest New Drugs2001https://conductscience.org/library/papers/11291837PubMed
11291829Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.Invest New Drugs2001https://conductscience.org/library/papers/11291829PubMed
8913837Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.Invest New Drugs1996https://conductscience.org/library/papers/8913837PubMed
8575564Acylfulvenes, a new class of potent antitumor agents.Experientia1996https://conductscience.org/library/papers/8575564PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2402017

GET https://conductscience.org/api/papers/v1/2402017/authors